Rajan P Kulkarni, MD
Dermatology · Portland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · University Professional Services · 1,683 clinicians in this group
Hospitals listed: OHSU Hospital and Clinics. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kulkarni’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A113764 · Current
Licensed to practise in California · since 2010 · expires 2028-05-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- OHSU Hospital and ClinicsPortland, ORAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Oregon Health and Science University, which runs 2 hospitalsHome of Knight Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.31 (1.1 to 1.51), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.83 (5.37 to 8.29) · 3,784 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.733, Oct 2024 – Sep 2025
See every measure and the patient survey for OHSU Hospital and Clinics
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.31 (1.1 to 1.51) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.83 (5.37 to 8.29) · 3,784 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.733 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.38 (0.61 to 2.14) · 2,275 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 150.45 (118.94 to 181.96) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 197 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.7 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 273 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,434 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.07 to 0.43) · 7,501 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.06 to 0.42) · 7,980 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.42 (1.27 to 3.57) · 2,337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (1.24 to 3.31) · 3,615 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (7.55 to 14.42) · 2,153 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.35 (5.23 to 9.48) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.69 to 3.27) · 1,001 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.66 (0.18 to 1.14) · 6,661 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 56 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.838 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.8 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.936 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.381 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.174 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 180 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 320 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.9 · 120 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 223 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.5 · 142 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.6 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.9 to 6.3) · 952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.5 (8 to 11.4) · 952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.1 to 15.4) · 1,483 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,425 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 24% of those asked)
| Cleanliness | 2 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$3,693
Medicare paid this office $3,693 for 21 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 18 | $2,026 | $81 |
| Destruction of precancer skin growth, 1 growth | 12 | $744 | $44 |
Procedures Medicare counted
| Removal of skin lesions | 33 | More than 69% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 13 | More than 61% of doctors who do this |
Who their Medicare patients are
21 Original Medicare patients in 2024. Average age 63 · 85 and older 0% · Health risk score 3.73. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 62%.
The office billed $20,784, Medicare allowed $4,679 and paid $3,693; for 163 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 21 | 163 | 63 | 3.73 | $20,784 | $3,693 |
| 2023 | 28 | 181 | 66 | 2.84 | $25,469 | $4,809 |
| 2022 | 29 | 115 | 64 | 2.67 | $19,217 | $3,691 |
| 2020 | 11 | 49 | 70 | 1.49 | $4,652 | $944 |
| 2017 | 127 | 362 | 74 | 1.80 | $84,051 | $13,688 |
| 2016 | 88 | 267 | 72 | 2.04 | $53,478 | $7,650 |
| 2015 | 76 | 191 | 72 | 2.24 | $45,976 | $6,742 |
| 2014 | 32 | 97 | 72 | 2.04 | $19,571 | $3,257 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 23 | $2,309 | $80 |
| Destruction of precancer skin growth, 1 growth | 18 | $877 | $40 |
| Biopsy of related skin growth, first growth | 13 | $278 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $151 | $2 |
2022: 2 services
| Return visit (30+ min) | 18 | $1,522 | $80 |
| Destruction of precancer skin growth, 1 growth | 13 | $524 | $40 |
2017: 7 services
| Short return visit (20+ min) | 66 | $4,048 | $60 |
| Biopsy of single growth of skin and/or tissue | 20 | $1,647 | $82 |
| Destruction of skin growth, 1-14 growths | 12 | $1,300 | $100 |
| Short return visit (20+ min) | 24 | $1,099 | $33 |
| New patient visit (30+ min) | 12 | $829 | $69 |
| Destruction of precancer skin growth, 1 growth | 20 | $798 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 19 | $561 | $5 |
2016: 6 services
| Short return visit (20+ min) | 40 | $1,679 | $34 |
| New patient visit (30+ min) | 21 | $1,261 | $60 |
| Destruction of precancer skin growth, 1 growth | 19 | $907 | $41 |
| Biopsy of single growth of skin and/or tissue | 22 | $658 | $27 |
| Destruction of skin growth, 1-14 growths | 12 | $625 | $52 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $154 | $2 |
2015: 4 services
| New patient visit (30+ min) | 27 | $1,561 | $58 |
| Short return visit (20+ min) | 36 | $1,554 | $36 |
| Destruction of skin growth, 1-14 growths | 17 | $998 | $55 |
| Biopsy of single growth of skin and/or tissue | 12 | $336 | $28 |
2014: 2 services
| New patient visit (30+ min) | 11 | $703 | $64 |
| Short return visit (20+ min) | 12 | $558 | $43 |
Money from drug and device companies
$35 in 2024
| 2024 | 1 | 1 | None | $35 |
| 2023 | 1 | 1 | None | $5 |
| 2021 | 1 | 1 | $2,480 | $2,480 |
| 2019 | 1 | 5 | None | $376 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | None | $35 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Meals · 2024-04-23 | None | $35 |
See earlier years (2023, 2021, 2019)
2023: $5
| Merck Sharp & Dohme | None | $5 | 1 payment
|
2021: $2,480
| Regeneron Pharmaceuticals | Libtayo | $2,480 | 1 payment
|
2019: $376
| Genzyme | No Product Discussed | $376 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2021 | Their institution | $13,387 |
| Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2024 | Their institution | $4,352 |
| Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2023 | Their institution | $4,160 |
| Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2022 | Their institution | $4,150 |
| Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2025 | Their institution | $4,109 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (Cscc) · 2025 | This clinician | $1,322 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1902040777
- Licence
- CA A113764, OR MD186821California A113764: Current · expires 2028-05-31
- Trained
- University of California, Geffen School of Medicine, 2009
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
- Mailing address
- 3303 Sw Bond Ave Ste 16, Portland, OR, 97239
- NPI first listed
- 2009-04-23
- NPI last updated
- 2018-07-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 200 Med Plaza Bldg 465, Los Angeles, CA, 90095 · 751 S Bascom Ave, San Jose, CA, 95128